NDLI: Efficacy of Akatinol Memantine in Moderate Cognitive Impairments

Content Provider	Springer Nature Link
Author	Levin, O. S. Yunishchenko, N. A. Dudarova, M. A.
Copyright Year	2010
Abstract	A six-month open clinical trial of the efficacy of Akatinol was conducted in 40 patients with moderate cognitive impairments (MCI) using piracetam (20 patients) as reference agent; mean age was 67.7 ± 7.2 years. Patient status was evaluated using a number of scales, questionnaires, and neuropsychological tests prior to treatment and at three and six months of treatment. Akatinol was given at a dose of 10 mg/day, and 20 patients received piracetam at a dose of 1200 mg/day. Studies were completed by 38 patients (95%) in the Akatinol arm and 18 (90%) in the piracetam arm. In the group treated with Akatinol, 5% reported deterioration, 20% no change, 35% moderate improvement, 25% marked improvement, and 15% great improvement. In the Akatinol arm, the proportion of patients without effects was significantly lower, while the proportions of patients with marked and great improvements were significantly higher than in the piracetam arm. Overall evaluation of cognitive functions on the MMSE scale showed significant increases in both groups by the end of the third month, though only patients receiving Akatinol maintained the improvements to the end of the sixth month. Akatinol treatment also produced positive changes in the symptoms of depression, subjective symptoms, and quality of life. More marked positive changes were seen in the dysregulatory type of MCI than in the amnestic type of MCI. The concept of MCI with a high risk of transformation to dementia is introduced; in this situation, treatment with Akatinol may be particularly relevant.
Starting Page	926
Ending Page	933
Page Count	8
File Format	PDF
ISSN	00970549
Journal	Neuroscience and Behavioral Physiology
Volume Number	40
Issue Number	8
e-ISSN	1573899X
Language	English
Publisher	Springer US
Publisher Date	2010-08-04
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	moderate cognitive impairment dementia Akatinol memantine piracetam Behavioural Sciences Neurobiology Neurosciences
Content Type	Text
Resource Type	Article
Subject	Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia

Correction of Subdementia Cognitive Impairments in Patients with Cerebral Ischemia

Efficacy and safety of memantine in Lewy body dementia

Cognitive Impairments in Progression of Parkinson’s Disease

Efficacy of akatinol memantine in moderate cognitive impairments.

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Comparative Analysis of Cognitive Impairments in Lewy Body Dementia and Alzheimer's Disease

Positron Emission Tomography Patterns in Cognitive Impairment in Patients with Multiple Sclerosis

Post-Stroke Cognitive Impairments

Efficacy of Akatinol Memantine in Moderate Cognitive Impairments

Similar Documents

Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia

Correction of Subdementia Cognitive Impairments in Patients with Cerebral Ischemia

Efficacy and safety of memantine in Lewy body dementia

Cognitive Impairments in Progression of Parkinson’s Disease

Efficacy of akatinol memantine in moderate cognitive impairments.

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Comparative Analysis of Cognitive Impairments in Lewy Body Dementia and Alzheimer's Disease

Positron Emission Tomography Patterns in Cognitive Impairment in Patients with Multiple Sclerosis

Post-Stroke Cognitive Impairments

Efficacy of Akatinol Memantine in Moderate Cognitive Impairments